Jubilant Pharmova recovers: ICICI Securities
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated